CARxALL Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia
- Coordinator
- Onechain Immunotherapeutics S.l., Spain
- Runs
- 1 April 2023 to 31 July 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €2.5m
- Partners
- 3 organisations in 2 countries
- Type
- European Innovation Council
- Grant agreement
- 101113067
What the project is doing
In the project's own words, from its summary on CORDIS.
R/R T-ALL remains a major clinical challenge. Despite improved survival rates thanks to intensive chemotherapy regimens, event-free (EFS) and overall (OS) survival remains <70% and R/R T-ALL has a particularly poor outcome. There are currently no potential curative options for R/R T-ALL beyond hematopoietic stem cell transplantation (HSCT) and conventional chemotherapy, which is linked to large trade-offs in toxicities.
Sadly, >90% of patients with R/R T-ALL/LL ultimately die. Strategies targeting T-cell malignancies using immunotherapies (including CARTs) remain challenging because of the shared expression of target antigens between normal and malignant T-cells, ultimately leading to life-threatening immunodeficiency due to T-cell aplasia and fratricide of CARTs, which limits their therapeutic efficacy. Here, we propose a unique and innovative approach to address this unmet clinical need based on the dual targeting of two specific antigens with expression restricted to T-cell lymphoblasts.
Our consortium aims to provide a cost-effective immunotherapeutic alternative for most of the R/R T-ALL patients by the dual targeting of two tnon-fratricide antigens using our scalable, HLA-independent, allogenic, off-the-shelf, proprietary platform of CORD-GDT cells, thus overcoming the challenges of harvesting sufficient numbers of functional effector T cells from multi-treated patients with advanced disease while avoiding the toxicities derived from other shared antigens between healthy and malignant T cells .
Our strategy will be preclinically assayed using cutting-edge experimental models, and we will mature and scale-up the proprietary platform of universal CORD-GDT cells redirected against these two non-fratricide antigens, expected to provide superior effector features and contribute to ad-hoc point-of-care treatment with cost-effective, ready-to-use and off-the-shelf effector cells.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Onechain Immunotherapeutics S.l. | Barcelona | Spain | Coordinator |
| Fundacio Institut De Recerca Contra La Leucemia Josep Carreras | Badalona | Spain | Third party |
| Instituto De Biologia Experimental E Tecnologica | Oeiras | Portugal | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI